肿瘤免疫学中的MHC II类分子：预后标志物及免疫调节靶点

MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation.

作者信息

Chamuleau M E D, Ossenkoppele G J, van de Loosdrecht A A

机构信息

Department of Haematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

出版信息

Immunobiology. 2006;211(6-8):619-25. doi: 10.1016/j.imbio.2006.05.005. Epub 2006 Jul 7.

DOI:10.1016/j.imbio.2006.05.005

PMID:16920500

Abstract

MHC class II molecules presenting MHC class II restricted antigens play an important role in the activation of CD4+ T cells, which are the central orchestrating cells of an immune response. This review focuses on the particular role of MHC class II molecules in tumour immunology. The MHC class II antigen presentation pathway and the expression of MHC class II molecules on tumour cells related to clinical outcome is discussed. Improving the MHC class II tumour antigen presentation pathway, for instance by downregulation of the invariant chain or modulation of HLA-DO expression, offers many opportunities for developing new modalities of immunotherapy.

摘要

呈递MHC II类限制性抗原的MHC II类分子在CD4+ T细胞的激活中发挥重要作用，而CD4+ T细胞是免疫反应的核心协调细胞。本综述聚焦于MHC II类分子在肿瘤免疫学中的特殊作用。讨论了MHC II类抗原呈递途径以及肿瘤细胞上MHC II类分子的表达与临床结果的关系。改善MHC II类肿瘤抗原呈递途径，例如通过下调恒定链或调节HLA-DO表达，为开发新的免疫治疗方式提供了许多机会。